Avidity Biosciences (RNA) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
10.9M
Operating Income
-378.9M
-3,477.43%
Net Income
-322.3M
-2,957.71%
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
138.9M
Shareholders Equity
1.4B
Debt to Equity
0.10
Cash Flow Metrics
Operating Cash Flow
-243.7M
Free Cash Flow
-307.9M
Revenue & Profitability Trend
Avidity Biosciences Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 10.9M | 9.6M | 9.2M | 9.3M | 6.8M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 389.8M | 245.2M | 188.1M | 127.4M | 51.1M |
| Operating Income | -378.9M | -235.6M | -178.9M | -118.1M | -44.3M |
| Pre-tax Income | -322.3M | -212.2M | -174.0M | -118.0M | -44.4M |
| Income Tax | - | - | - | - | - |
| Net Income | -322.3M | -212.2M | -174.0M | -118.0M | -44.4M |
| EPS (Diluted) | - | -$2.91 | -$3.34 | -$5.70 | -$2.05 |
Income Statement Trend
Avidity Biosciences Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.5B | 611.3M | 622.9M | 411.1M | 331.7M |
| Non-Current Assets | 21.6M | 17.2M | 15.9M | 16.4M | 2.2M |
| Total Assets | 1.6B | 628.6M | 638.8M | 427.6M | 333.9M |
| Liabilities | |||||
| Current Liabilities | 98.0M | 80.7M | 51.9M | 29.7M | 14.6M |
| Non-Current Liabilities | 40.9M | 47.1M | 8.8M | 16.5M | 13.1M |
| Total Liabilities | 138.9M | 127.8M | 60.7M | 46.2M | 27.7M |
| Equity | |||||
| Total Shareholders Equity | 1.4B | 500.8M | 578.1M | 381.4M | 306.2M |
Balance Sheet Composition
Avidity Biosciences Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -322.3M | -212.2M | -174.0M | -118.0M | -44.4M |
| Operating Cash Flow | -243.7M | -107.5M | -131.3M | -98.3M | -36.2M |
| Investing Activities | |||||
| Capital Expenditures | -7.1M | -4.2M | -2.8M | -3.7M | -1.1M |
| Investing Cash Flow | -854.2M | -130.1M | -190.0M | -82.5M | -7.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | 0 | 0 |
| Financing Cash Flow | 1.0B | 91.7M | 344.8M | 163.4M | 247.5M |
| Free Cash Flow | -307.9M | -123.3M | -139.1M | -98.6M | -38.2M |
Cash Flow Trend
Avidity Biosciences Key Financial Ratios
Valuation Ratios
Forward P/E
-9.86
Price to Book
2.71
Price to Sales
403.26
PEG Ratio
-9.86
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-8,360.90%
Return on Equity
-34.19%
Return on Assets
-22.47%
Financial Health
Current Ratio
16.91
Debt to Equity
0.45
Beta
0.95
Per Share Data
EPS (TTM)
-$3.00
Book Value per Share
$11.03
Revenue per Share
$0.07
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| rna | 3.6B | - | 2.71 | -34.19% | 0.00% | 0.45 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.